Outcomes-Based Contract Structure
Outcomes-based contracts tie gene therapy payment to clinical outcomes. The payer pays the full price upfront; if the therapy achieves the promised outcome (e.g., no hemophilia bleeds for 5 years), no rebate is owed. If the therapy fails to achieve the outcome, the manufacturer provides a rebate or refund proportional to the shortfall. This structure shifts some financial risk from the payer to the manufacturer.
Implementation Challenges
Implementing outcomes-based contracts requires: (1) data infrastructure to track patient outcomes over time; (2) legal expertise to draft enforceable contract terms; (3) patient tracking — patients may change health plans, making outcome tracking difficult; and (4) manufacturer willingness — not all manufacturers are willing to enter outcomes-based contracts.
Installment Payment Models
IQ Insight
Installment payment models — paying for gene therapy in annual installments over 5–10 years rather than upfront — are an alternative to outcomes-based contracts. Installment payments reduce the upfront financial burden and naturally tie payment to ongoing benefit. If the patient changes health plans, payment obligations transfer to the new plan. Several states are exploring installment payment models for gene therapies.